Sickle cell anemia: Experience in a center;Drepanocitosis: Experiencia de un centro

Anales de Pediatria

Volumn 58, Issue 2, 2003, Pages 95-99

  Gomez Chiari M ^a   Tusell Puigbert, J ^a   Ortega Aramburu, J ^a  

^a HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

Hemoglobinopathy; Hydroxyurea; Sickle cell disease

Indexed keywords

HYDROXYUREA;

ADOLESCENT; AFRICA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CENTRAL AMERICA; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; EARLY DIAGNOSIS; EPIDEMIOLOGICAL DATA; FEMALE; GAMBIA; GENETIC COUNSELING; HUMAN; INFECTION; MALE; MOROCCO; NEGRO; PAIN; PEDIATRIC HOSPITAL; RETROSPECTIVE STUDY; SENEGAL; SEX RATIO; SICKLE CELL ANEMIA; SPAIN; SPLENECTOMY; STROKE; VEIN OCCLUSION;

EID: 4744366958     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042966     Document Type: Article

References (25)

1. Rosse WF, Narla M, Petz LD, Steinberg MH. New views of sickle cell disease pathophysiology and treatment. Hematology 2001;42:2-17.
2. Yaster M, Kost-Byerly S, Maxwell LG. The management of pain in sickle cell disease. Pediatr Clin North Am 2000;47:100-5.
3. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease: Rates and risk factors. N Engl J Med 1991;325:11-6.
4. Quinn C, Buchanan G. The acute chest syndrome of sickle cell disease. J Pediatr 1999;135:420-33.
5. Miller S, Wright E, Abboud M, Berman B, Files B, Scher C, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the stroke prevention trial (STOP) in sickle cell anemia. J Pediatrics 2001;139:601-8.
6. Powars D. Sickle cell disease. Pediatrics 1998;10:49-52.
7. Miller ST, Sleeper LA, Pegelow C, Enos L, Wang W, Weiner S, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83-9.
8. Adams RJ, Ohene-Frempong K, Wang W. Sickle cell and the brain. Hematology 2001;41:31-46.
9. Miller S, Macklin E, Pegelow C, Kinney T, Sleeper L, Bello J, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the cooperative study of sickle cell disease. J Pediatrics 2001;139:310-9.
10. Ware R, Zimmerman SA. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94:3022-6.
11. Wang W, Enos L, Gallagher D, Thompson R, Guarini L, Vichinsky E, et al. Neuropsychologic performance in school-aged children with sickle cell disease: A report from the cooperative study of sickle cell disease. J Pediatrics 2001;139:301-9.
12. Adams R, Mckie V, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusion in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998;339:5-11.
13. Mantadakis E, Cavenders JD. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatrics Hematol Oncol 1999;21:518-22.
14. Miller S, Sleeper L, Pegelow C, Enos L, Wang W, Weiner S, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83-9.
15. Stancy J, Rusellew M. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: Implications for pharmacological intervention. Am J Pediatr Hematol Oncol 1999;21:401-6.
16. Wigfall D, Ware R, Burchinal M, Kinney T, Foreman J. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatrics 2000;136:670-9.
17. Wethers D. Sickle cell disease in childhood: Part I. Laboratory diagnosis, pathophysiology and health maintenance. Am Family Physician 2000;62:901-7.
18. Papassotiriou I, Stamoulakatou A. Hydroxyurea induced erythropoiein secretion in sickle cell syndromes may contribute in their HbF increase. Blood 1998;92:160a.
19. Hillery CA. Potencial therapeutic approaches for the treatment of vaso-occlusion in sickle cell disease. Hematology 1998;5:151-5.
20. Styles LA, Lubin B, Vichinsky E, Lawrence S. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle ell patients treated with hydroxyurea. Blood 1997;89:2554-9.
21. Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:420-31.
22. Blythe J. Better screening need for sickle cell and talassemia. BMJ 2000;231:69.
23. Cabot A, Casado M, Barberán J. Screening neonatal de drepanocitosis en el consorci sanitari de Mataró. Justificación y primeros resultados. An Esp Pediatr 1998;49:57-60.
24. Ware RE, Eggleston B, Redding-Lallinger R, Redding R, Wang W, Smith K, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002;99:10-4.
25. Wang W, Wynn L, Rogers Z, Scott J, Lane P, Ware R. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001;139:790-6.